Please provide your email address to receive an email when new articles are posted on . “There’s a lot of hot topics right now in myeloma in general,” Mazzoni, hematologist with the Cleveland Clinic, ...

Please provide your email address to receive an email when new articles are posted on . Healio spoke with John Molina, MD, MEd, about research on the use of minimal residual disease testing in acute ...

Emilie Aschenbrenner, PharmD, BCOP, highlights how measurable residual disease (MRD) testing can support value-based care in multiple myeloma by guiding personalized treatment intensity, potentially ...

Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...

Ravi Vij, MD, MBA, discusses how measurable residual disease (MRD) testing is shaping treatment decisions in hematology and its potential to reduce costs and toxicity. Measurable residual disease (MRD ...

Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to bone marrow biopsies. Quest Diagnostics has announced the launch of a novel ...

Minimal residual disease (MRD) testing is poised to transform cancer care, according to John Truesdell, Chief Business Officer at Foresight Diagnostics. In a recent interview with Fierce, Truesdell ...

Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are ...